Abstract
Toll-like receptor 9 (TLR9) can sense pathogen DNA and CpG ODN or even self-DNA by trafficking assisted by Unc93B1, an endoplasmic reticulum (ER) transmembrane protein, from ER to endolysosomes or cell surface. In previous study, we found that an oligodeoxynucleotide with CCT repeats (SAT05f) could selectively inhibit TLR7/9 activation. However, the mechanism for the inhibitory activity of SAT05f is still unknown. In present research, it was found that SAT05f could inhibit CpG ODN-induced the intracellular trafficking of TLR9 and Unc93B1 with feedback the responses of decreased surface TLR9 and enhanced TLR9 mRNA expression but not influence TLR9 protein level by using human plasmacytoid dendritic cell line CAL-1 cells, suggesting that SAT05f inhibits TLR9 activation by restraining TLR9 trafficking. Since the mitochondrial DNA released from injured tissue can cause systemic inflammatory response syndrome (SIRS), this study may provide valuable data for prevention and treatment of SIRS and rescue severe trauma patients.
Keywords: Intracellular trafficking, immunosuppression, oligodeoxynucleotide, toll-like receptor 9.
Current Pharmaceutical Biotechnology
Title:An Oligodeoxynucleotide with CCT Repeats Restrains CpG ODN-Induced TLR9 Trafficking
Volume: 15 Issue: 9
Author(s): Xiaoling Zhang, Wei Sun, Xiuli Wu, Hua Wang, Youyou Yan, Sheng Guo, Dandan Song, Hainan Li, Shuang Gao, Luowei Wang, Yongli Yu and Liying Wang
Affiliation:
Keywords: Intracellular trafficking, immunosuppression, oligodeoxynucleotide, toll-like receptor 9.
Abstract: Toll-like receptor 9 (TLR9) can sense pathogen DNA and CpG ODN or even self-DNA by trafficking assisted by Unc93B1, an endoplasmic reticulum (ER) transmembrane protein, from ER to endolysosomes or cell surface. In previous study, we found that an oligodeoxynucleotide with CCT repeats (SAT05f) could selectively inhibit TLR7/9 activation. However, the mechanism for the inhibitory activity of SAT05f is still unknown. In present research, it was found that SAT05f could inhibit CpG ODN-induced the intracellular trafficking of TLR9 and Unc93B1 with feedback the responses of decreased surface TLR9 and enhanced TLR9 mRNA expression but not influence TLR9 protein level by using human plasmacytoid dendritic cell line CAL-1 cells, suggesting that SAT05f inhibits TLR9 activation by restraining TLR9 trafficking. Since the mitochondrial DNA released from injured tissue can cause systemic inflammatory response syndrome (SIRS), this study may provide valuable data for prevention and treatment of SIRS and rescue severe trauma patients.
Export Options
About this article
Cite this article as:
Zhang Xiaoling, Sun Wei, Wu Xiuli, Wang Hua, Yan Youyou, Guo Sheng, Song Dandan, Li Hainan, Gao Shuang, Wang Luowei, Yu Yongli and Wang Liying, An Oligodeoxynucleotide with CCT Repeats Restrains CpG ODN-Induced TLR9 Trafficking, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/1389201015666141031114708
DOI https://dx.doi.org/10.2174/1389201015666141031114708 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]
Current Cancer Drug Targets A Rare Diagnosis in a Patient With Pelvic Pain: Adnexal Schwannoma
Current Medical Imaging Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Cationicity and Hydrophobicity Enhance the Cytotoxic Potency of Phoratoxin C Anticancer Peptide Analogues against Triple Negative Breast Cancer Cells
Current Bioactive Compounds Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Current Topics in Medicinal Chemistry A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Using Simulation in Clinical Education: Psoriasis Area and Severity Index (PASI) Score Assessment
Current Rheumatology Reviews RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics